The clinical use of biomarkers as prognostic factors in Ewing sarcoma

Table 6 Outcome for biological markers: karyotype

Author	Year	Biomarker	Pt number	P
Tarkannen et al, Cancer Genet Cytogenet 114, 35-41	1999	1q	28	NS
Hattinger et al, Br J Cancer 86, 1763-9[63]	2002	1q	134	0.046
Tarkannen et al, Cancer Genet Cytogenet 114, 35-41	1999	6p2.1	28	0.004
Lopez-Guerrero et al, Lab Invest 81 (6), 803-14[64]	2001	9p21 locus	19	0.005
Hattinger et al, Br J Cancer 86, 1763-9[63]	2002	16q	134	0.008
Hattinger et al, Genes Chromosomes Cancer 24 (3), 243-54[65]	1999	Chr 1	58	0.004
Tarkannen et al, Cancer Genet Cytogenet 114, 35-41	1999	Chr 8	28	NS
Hattinger et al, Genes Chromosomes Cancer 24 (3), 243-54[65]	1999	Chr 8	58	0.17
Hattinger et al, Br J Cancer 86, 1763-9[63]	2002	Chr 8	134	NS
Tarkannen et al, Cancer Genet Cytogenet 114, 35-41	1999	Chr 12	28	NS
Hattinger et al, Genes Chromosomes Cancer 24 (3), 243-54 [65]	1999	Chr 12	58	0.63
Hattinger et al, Br J Cancer 86, 1763-9[63]	2002	Chr 12	134	0.009
Ohali et al, J Clin Oncol 21, 3836-43[52]	2003	Telomerase activity	31	0.0001
Avigad et al, Clin Cancer Res 13 (19), 5777-83[54]	2007	Telomerase length	32	0.015

ISSN: 2045-3329